The treatment of venous thromboembolism in special populations

Thrombosis Research

Volumn 119, Issue 4, 2007, Pages 391-402

  Rondina, Matthew T ^a   Pendleton, Robert C ^a   Wheeler, Michelle ^a   Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiphospholipid antibody syndrome; Heparin induced thrombocytopenia; Low molecular weight heparin; Obesity; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; NADROPARIN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLEEDING; BODY MASS; CANCER PATIENT; CANCER SURVIVAL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; GENETIC PREDISPOSITION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERHOMOCYSTEINEMIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LUNG EMBOLISM; MORBID OBESITY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOPHILIA; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HEPARIN; HUMANS; NEOPLASMS; OBESITY, MORBID; RECURRENCE; RENAL INSUFFICIENCY; THROMBOEMBOLISM;

EID: 33846416195     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.05.015     Document Type: Review

References (78)

1. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
2. Kim V., and Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am 19 (2001) 839-859
3. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 401S-428S
4. McRae S.J., and Ginsberg J.S. Initial treatment of venous thromboembolism. Circulation 110 (2004) I3-I9
5. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 110 (2004) I10-I18
6. Bates S.M., and Ginsberg J.S. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 351 (2004) 268-277
7. Hirsh J. Heparin. N Engl J Med 324 (1991) 1565-1574
8. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 188S-203S
9. Francis J.L., and Groce III J.B. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy 24 (2004) 108S-119S
10. Levine M.N., Hirsh J., Gent M., Turpie A.G., Cruickshank M., Weitz J., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154 (1994) 49-56
11. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 (1993) 315-328
12. Spinler S.A., Inverso S.M., Cohen M., Goodman S.G., Stringer K.A., and Antman E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146 (2003) 33-41
13. Thorevska N., Amoateng-Adjepong Y., Sabahi R., Schiopescu I., Salloum A., Muralidharan V., et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs. enoxaparin. Chest 125 (2004) 856-863
14. Casserly L.F., and Dember L.M. Thrombosis in end-stage renal disease. Semin Dial 16 (2003) 245-256
15. Tveit D.P., Hypolite I.O., Hshieh P., Cruess D., Agodoa L.Y., Welch P.G., et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39 (2002) 1011-1017
16. Cadroy Y., Pourrat J., Baladre M.F., Saivin S., Houin G., Montastruc J.L., et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 63 (1991) 385-390
17. Goudable C., Saivin S., Houin G., Sie P., Boneu B., Tonthat H., et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 59 (1991) 543-545
18. Busby L.T., Weyman A., and Rodgers G.M. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67 (2001) 54-56
19. Sanderink G.J., Liboux A.L., Jariwala N., Harding N., Ozoux M.L., Shukla U., et al. Enoxaparin pharmacokinetics and pharmacodynamics in obese subjects. J Am Coll Cardiol 37 suppl A (2001) 229a
20. Gerlach A.T., Pickworth K.K., Seth S.K., Tanna S.B., and Barnes J.F. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20 (2000) 771-775
21. Laposata M., Green D., Van Cott E.M., Barrowcliffe T.W., Goodnight S.H., and Sosolik R.C. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122 (1998) 799-807
22. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., and Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 119 (1993) 874-881
23. Lackie C.L., Luzier A.B., Donovan J.A., Feras H.I., and Forrest A. Weight-based heparin dosing: clinical response and resource utilization. Clin Ther 20 (1998) 699-710
24. Yee W.P., and Norton L.L. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 55 (1998) 159-162
25. Spruill W.J., Wade W.E., Huckaby W.G., and Leslie R.B. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 58 (2001) 2143-2146
26. Barba R., Marco J., Martin-Alvarez H., Rondon P., Fernandez-Capitan C., Garcia-Bragado F., et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 3 (2005) 856-862
27. Bazinet A., Almanric K., Brunet C., Turcotte I., Martineau J., Caron S., et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116 (2005) 41-50
28. Sanderink G.J., Le Liboux A., Jariwala N., Harding N., Ozoux M.L., Shukla U., et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72 (2002) 308-318
29. Wilson S.J., Wilbur K., Burton E., and Anderson D.R. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31 (2001) 42-48
30. Al-Yaseen E., Wells P.S., Anderson J., Martin J., and Kovacs M.J. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 3 (2005) 100-102
31. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
32. Buller H.R., and the MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA) in the initial treatment of venous thromboembolism in obese patients. Blood 104 (2004) 203a
33. Lee A.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003) I17-I21
34. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 (2000) 3078-3083
35. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
36. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
37. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
38. Prandoni P., Lensing A.W., Buller H.R., Carta M., Cogo A., Vigo M., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339 (1992) 441-445
39. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., and Buller H.R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82 (1999) 947-952
40. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
41. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
42. Arnout J., and Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 1 (2003) 931-942
43. Schulman S., Svenungsson E., and Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104 (1998) 332-338
44. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
45. Simonneau G., Sors H., Charbonnier B., Page Y., Laaban J.P., Azarian R., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l'Embolie Pulmonaire. N Engl J Med 337 (1997) 663-669
46. Rosove M.H., and Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
47. Ruiz-Irastorza G., Khamashta M.A., Hunt B.J., Escudero A., Cuadrado M.J., and Hughes G.R. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 162 (2002) 1164-1169
48. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., and Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
49. Oden A., and Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 325 (2002) 1073-1075
50. al-Sayegh F.A., Ensworth S., Huang S., Stein H.B., and Klinkhoff A.V. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 24 (1997) 1716-1718
51. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003) 1133-1138
52. Finazzi G., Marchioli R., Brancaccio V., Schinco P., Wisloff F., Musial J., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005) 848-853
53. Baglin T.P., Keeling D.M., and Watson H.G. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 132 (2006) 277-285
54. Douketis J.D., Foster G.A., Crowther M.A., Prins M.H., and Ginsberg J.S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160 (2000) 3431-3436
55. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., and Melton III L.J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160 (2000) 761-768
56. Douketis J.D., Crowther M.A., Foster G.A., and Ginsberg J.S. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med 110 (2001) 515-519
57. Breddin H.K., Hach-Wunderle V., Nakov R., and Kakkar V.V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 344 (2001) 626-631
58. Siragusa S., Cosmi B., Piovella F., Hirsh J., and Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100 (1996) 269-277
59. Lensing A.W., Prins M.H., Davidson B.L., and Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155 (1995) 601-607
60. Luk C., Wells P.S., Anderson D., and Kovacs M.J. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111 (2001) 270-273
61. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338 (1998) 409-415
62. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 (2005) 416-422
63. Hull R., Hirsh J., Jay R., Carter C., England C., Gent M., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307 (1982) 1676-1681
64. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 204S-233S
65. Dentali F., Manfredi E., Crowther M., and Ageno W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 3 (2005) 2121-2123
66. Kearon C., Crowther M., and Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51 (2000) 169-185
67. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
68. Lindmarker P., Schulman S., Sten-Linder M., Wiman B., Egberg N., and Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation. Thromb Haemost 81 (1999) 684-689
69. De Stefano V., Martinelli I., Mannucci P.M., Paciaroni K., Chiusolo P., Casorelli I., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
70. De Stefano V., Martinelli I., Mannucci P.M., Paciaroni K., Rossi E., Chiusolo P., et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 113 (2001) 630-635
71. Baglin T., Luddington R., Brown K., and Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523-526
72. Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., and Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
73. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
74. Vossen C.Y., Walker I.D., Svensson P., Souto J.C., Scharrer I., Preston F.E., et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 25 (2005) 1992-1997
75. Greaves M., and Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease annotation. Br J Haematol 109 (2000) 699-703
76. Oger E., Lacut K., Le Gal G., Couturaud F., Guenet D., Abalain J.H., et al. J Thromb Haemost 4 (2006) 793-799
77. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. NEJM 354 (2006) 1578-1588
78. HOPE Investigators. NEJM 354 (2006) 1567-1577